Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

319P - Serum based test to assist preoperative decision making in suspected gallbladder cancer

Date

27 Jun 2024

Session

Poster Display session

Presenters

Ghada Nouairia

Citation

Annals of Oncology (2024) 35 (suppl_1): S119-S161. 10.1016/annonc/annonc1481

Authors

G. Nouairia1, M. Cornillet1, H. Jansson2, A. Bergquist2, E. Sparrelid2

Author affiliations

  • 1 Karolinska Institutet, Huddinge/SE
  • 2 Karolinska University Hospital and Karolinska Institute - Huddinge, Stockholm/SE

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 319P

Background

Gallbladder cancer (GBC) and benign inflammatory disease of the gallbladder are clinical entities that are very difficult to separate prior to histological analysis, especially in the xanthogranolumatous cholecystitis condition. Currently, there is no available accurate preoperative method that can distinguish malignant from benign diagnosis of the gallbladder, leading to a number of extended resections not indicated should the postoperative pathology have been known prior to surgery.

Methods

This is a retrospective observational single-centre study including patients operated, under suspision of GBC, with bisegmentectomy (or wedge resection) and lymph adenectomy at Karolinska University Hospital during the years 2009-2020. Preoperative plasma from a prospective biobank was analysed using the 7586 proteomics panel from SomaLink and the clinical data of the patients, including results from the histological analysis, were collected. We analyzed the proteomic data using machine learning methods (LASSO regression) to select proteins with high potential to predict if the patients have benign disease or malignant tumour. We also identified the proteins that are linked to the difference between GBC and benign disease using Mann-Whitney statistical test of significance and elastic net regression.

Results

We identified 13 serum proteins with high predictive potential. A linear combination of 6 to 8 of these proteins can distinguish GBC from benign disease with a an accuracy of 94 to 99 %. These 13 proteins were capable to cluster the patients into two groups largely corresponding to the benign and the GBC patients. However, 10 % of the patients were placed in a “gray-zone” where the groups superpose. In addition, we list 604 proteins with strong linkage to the difference between benign disease and malignant tumours in the gallbladder. These proteins are mainly involved in the axon guidance pathways, the coagulation and complement cascades pathway and other pathways known in tumour progression.

Conclusions

Proteins in the pre-operative serum are informative of the benign or GBC patients. A small number of these proteins (6 to 8) can be screened and used to assist in decision making for suspected gallbladder cancer.

Legal entity responsible for the study

Ernesto Sparellid.

Funding

Karolinska Institute, Karolinska University Hospital.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.